We present a case of a 42-year-old male patient affected by unresectable, chemorefractory cholangiocarcinoma, with prior placement of biliary stent. Because of the absence of extrahepatic metastases, he was submitted to liver-direct therapy with 90 Y-microspheres. 18 F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) performed before the procedure showed intense tracer uptake in the hepatic lesion and along the biliary stent. The patient underwent radioembolization with 90 Y-resin spheres (1.1 GBq). 18 F-FDG PET-CT, acquired 6 weeks after the procedure, showed no response of the hepatic lesion and the appearance of an area of markedly increased uptake extending through the inferior vena cava into the right atrium, confirmed as extensive tumor thrombus at the enhanced multislice CT subsequently performed. 18 F-FDG PET-CT proved to be a useful imaging tool not only for the evaluation of metabolic response but also for the early detection of extrahepatic progression after 90Y-radioembolization.
A 42-year-old male patient without any significant medical past history presented with jaundice and abdominal pain on his right side in July 2017. Ultrasound and computed tomography (CT) scan demonstrated a large tumor in the central part of the liver without any abdominal lymph nodes or extrahepatic localizations. Fine-needle biopsy and histological examination diagnosed an intrahepatic cholangiocarcinoma (ICC). In order to reduce the bilirubin levels, a biliary stent was implanted. Subsequently, the patient was submitted to chemotherapy. After 1 month due the appearance of toxicity, chemotherapy was stopped.
Since tumor was exclusively localized to the liver, a locoregional therapy with 90 Y-microspheres was considered. 99m Tc-macroaggregated albumin scan performed before the radioembolization procedure did not reveal any lung shunting of extrahepatic uptake. 18 F-fluorodeoxyglucose positron emission tomography-computed tomography (FGD PET-CT), performed before the treatment with 90 Y-microspheres [ Figure 1 ], showed an area of focal tracer uptake in the IV segment of the liver, with a maximum standardized uptake value (SUV max) of 12.8. Furthermore, an area of 18 F-FDG accumulation was detected along the hepatobiliary stent, most likely due to inflammation. Radioembolization was performed through the injection of 1.1 Gbq of 90 Y-resin microspheres (SIRS-Spheres ® , Sirtex Medical, Lane Cove, Australia). No side effects were registered. The patient was submitted to 90 Y-PET scan to assess the microspheres' distribution pattern. [1] the images demonstrated poor tumor uptake with the majority of the dosage distributing to nontarget areas of the left lobe [ Figure 2 ]. No significant toxicity or relevant symptomatology was registered in the weeks following the procedure. F-FDG uptake (SUV max 20.8) extending through the inferior vena to right atrium. The subsequently performed enhanced multislice CT axial slice showed an arterial-phase gross filling defect (dimensions 42 mm × 33 mm) in the right atrium, consistent with tumor thrombus. Death occurred 3 months after the 90 Y-radioembolization procedure.
Despite many advances in diagnosis and therapy, the management of ICC still remains a challenge for physicians. Surgery is the first choice but is often practicable due to advanced presentation. [2, 3] Patients with unresectable ICC are often submitted to chemotherapy but with limited benefits on survival. [4] In this panorama, locoregional treatments such as transarterial chemoembolization and radioembolization with 90 Y-loaded may be considered. [5] The median overall survival of ICC patients treated with 90 Y-microspheres reported in previously published papers resulted of 15.2 months from the procedure, [6] which is the optimal imaging modality and the best time point for assessing response after 90 Y RE has not been established yet. Identifying patients with poor clinical outcome is becoming of utmost importance in oncology to timely start as early as possible adjuvant or palliative treatments. [7, 8] We present a rare and fatal complication in a nonresponder ICC patient after 90 Y-radioembolization. This case points out the usefulness of metabolic imaging with 18 F-FDG not only for monitoring the response of the hepatic lesion after 90 Y-radioembolization but also for the early detection of extrahepatic progression.
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